Angela R. Bradbury, MD
Assistant Professor, Department of Medicine
2013-2014 BCRF Project:
Cancer Risk Evaluation Program
University of Pennsylvania School of Medicine
(Conquer Cancer Foundation of ASCO 2013 Advanced Clinical Research Award)
BRCA1/2 Genetic testing for breast cancer susceptibility can guide cancer risk management and improve patient survival. However, most individuals with a personal or family history of breast cancer do not have a BRCA1/2 mutation. Research has revealed that mutations in other genes, such as PalB2, CHEK2 and PTEN, are associated with elevated risks of breast cancer.
Yet, the clinical utility of these genes remains unknown. And, there is no data regarding patient experiences, and the risks, benefits and clinical utility of multiplex testing for breast cancer susceptibility. The clinical availability of multiplex testing without clear utility demonstrates the urgent need for multidisciplinary translational research that focuses on how to advance gene discoveries into clinical practice in a way that benefits the health and minimizes the risks for cancer patients. The overall goal of Dr. Bradbury’s research is to evaluate the risks and benefits of multiplex genetic testing for breast cancer susceptibility.
Dr. Angela Bradbury is an Assistant Professor in the Department of Medicine, Division of Hematology-Oncology at the University of Pennsylvania. She is a physician in the Cancer Risk Evaluation Program and also has a secondary appointment in the Department of Medical Ethics and Health Policy. Dr. Bradbury is a medical oncologist with specialized training in breast oncology, clinical cancer genetics and medical ethics. She has been developing and leading translational genetic research focused on the clinical implementation of genetic medicine to promote the health of individuals, families and communities since 2003. This includes studies evaluating delivery and dissemination of genetic services, communication of genetic information in clinical care and within families and the impact of early communication of genetic risk in adolescent girls. She is the recipient of an American Cancer Society Mentored Research Scholar Award and American Society of Clinical Oncology (ASCO) Young Investigator Award and more recently multiple National Institutes of Health grants evaluating early determinants of breast cancer risk and psychosocial adjustment in teen girls (R01 CA138819 Daly/Bradbury) and novel cancer genetic delivery models to facilitate dissemination and implementation of cancer genetics (R01 CA160847-01A1 /R21CA164121-02).